Workflow
ST中珠前三季度营收4.33亿元同比增12.82%，归母净利润-3378.54万元同比增63.44%，毛利率下降2.39个百分点
Xin Lang Cai Jing·2025-10-30 10:24

Core Insights - ST Zhongzhu reported a revenue of 433 million yuan for the first three quarters of 2025, representing a year-on-year increase of 12.82% [1] - The company recorded a net profit attributable to shareholders of -33.78 million yuan, which is a 63.44% increase in losses compared to the previous year [1] - The basic earnings per share stood at -0.02 yuan [1] Financial Performance - The gross profit margin for the first three quarters of 2025 was 19.54%, a decrease of 2.39 percentage points year-on-year [2] - The net profit margin was -7.10%, an increase of 16.65 percentage points compared to the same period last year [2] - In Q3 2025, the gross profit margin improved to 21.74%, up 2.10 percentage points year-on-year and 1.57 percentage points quarter-on-quarter [2] - The net profit margin for Q3 2025 was -6.19%, which is an increase of 15.38 percentage points year-on-year but a decrease of 2.84 percentage points from the previous quarter [2] Expense Analysis - Total operating expenses for the period were 117 million yuan, a decrease of 31.24 million yuan year-on-year [2] - The expense ratio was 26.90%, down 11.59 percentage points from the same period last year [2] - Sales expenses decreased by 7.36%, management expenses decreased by 31.36%, and R&D expenses decreased by 12.57%, while financial expenses increased by 84.26% [2] Shareholder Information - As of the end of Q3 2025, the total number of shareholders was 20,200, a decrease of 258 from the end of the first half of the year, representing a decline of 1.26% [2] - The average market value of shares held per shareholder increased from 162,800 yuan to 189,500 yuan, reflecting a growth of 16.44% [2] Company Overview - ST Zhongzhu, established on June 27, 1994, is located in Zhuhai, Guangdong Province, and was listed on May 18, 2001 [3] - The company's main business segments include medical services (64.66%), real estate development (25.88%), pharmaceuticals and others (9.27%), and financing leasing (0.20%) [3] - The company operates within the pharmaceutical and biological industry, specifically in medical services and hospitals [3]